Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioblastoma 154Brain Neoplasms 73Glioma 69Central Nervous System Neoplasms 50Gliosarcoma 46Astrocytoma 37Melanoma 36Oligodendroglioma 29Neuroblastoma 17Neoplasm Metastasis 14Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 11Sarcoma, Ewing 10Sarcoma 10Neoplasms 10Medulloblastoma 10Recurrence 9Neuroendocrine Tumors 9Lymphoma 8Ependymoma 8Breast Neoplasms 8Small Cell Lung Carcinoma 7Rhabdomyosarcoma 7Diffuse Intrinsic Pontine Glioma 7Colorectal Neoplasms 7Carcinoma, Neuroendocrine 6Adenoma, Islet Cell 6Uveal Melanoma 5Spinal Cord Neoplasms 5Pheochromocytoma 5

Interventions

Temozolomide 2Bevacizumab 2Valproic Acid 1Therapeutics 1Sorafenib 1Sildenafil Citrate 1Radiotherapy 1Irinotecan 1Clomipramine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neurologic Manifestations × Temozolomide × Clear all
NCT02343549 2022-11-03

A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)

Wake Forest University Health Sciences

Phase 2 Terminated
13 enrolled 23 charts
CNS

Brain Neoplasms, Neurologic Manifestations

NCT00365222 2009-01-22

Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
1 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Neurologic Manifestations, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡